Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

EU antitrust regulators on Friday closed a four-year long investigation into Apple's rules for competing e-book and audiobook ...

Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.

Several institutional investors and hedge funds have recently modified their holdings of the business. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S in the second ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Quanta Dialysis Technologies has raised $60 million to expand its U.S. commercial presence for its Quanta dialysis system.

Below is our Corporate / M&A decisions update covering decisions in the second quarter of 2024. Decisions from the Delaware Court of Chancery ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...